Showing results (1-10 of 69) with videos related to
Sort By:
Pageof 7
Diabetologia|July 11, 2023
Socioeconomic aspects of incretin-based therapyThomas Karagiannis, Eleni Bekiari, Apostolos TsapasAnnals of Internal Medicine|December 14, 2020
In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitorsAris Liakos, Apostolos Tsapas, Eleni BekiariCore Evidence|March 30, 2017
Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapyThomas Karagiannis, Eleni Bekiari, Apostolos TsapasAnnals of Internal Medicine|March 1, 2021
KDIGO made 12 recommendations for managing diabetes with CKDThomas Karagiannis, Apostolos Tsapas, Eleni BekiariAnnals of Internal Medicine|July 21, 2020
Some glucose-lowering drugs reduce risk for major adverse cardiac eventsAris Liakos, Apostolos Tsapas, Eleni BekiariWorld Journal of Hepatology|October 13, 2018
Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief reviewEleni Gigi, Vasileios I Lagopoulos, Eleni BekiariCurrent Diabetes Reports|January 13, 2026
SGLT-2 Inhibitors and GLP-1 Receptor Agonists as Combination Therapy in Type 2 DiabetesAris Liakos, Thomas Karagiannis, Ioannis Avgerinos, et al.Mediterranean Journal of Rheumatology|April 10, 2023
JAK Inhibition in Patients with Rheumatoid Arthritis: Haemodynamic Effects and Impact on Micro- and Macrovascular Function. Study Design and RationalePanagiota Anyfanti, Elena Angeloudi, Eleni Pagkopoulou, et al.Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|December 11, 2019
Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of DapagliflozinIoannis Avgerinos, Aris Liakos, Apostolos Tsapas, et al.Diabetes Research and Clinical Practice|June 18, 2021
GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trialsApostolos Tsapas, Thomas Karagiannis, Ioannis Avgerinos, et al.Pageof 7